The 2024 ASCO Breakthrough Summit, hosted by the American Society of Clinical Oncology (ASCO), was held in Yokohama, Japan, from August 8 to 10. This annual scientific conference, themed "Shining a Light on Advances in Cancer Care," aimed to gather leaders and innovators in the field of oncology to discuss and share the latest research findings and technological innovations.

On July 26, 2024, in Shanghai, Shanghai Escugen Biotechnology Co., Ltd. ("Escugen") and Innolake Pharma Co., Ltd. ("Innolake") jointly announced that they have entered into a global exclusive licensing agreement for the application of Escugen's novel ADC technology platform, EZWi-Fit®, in the development of ADC products targeting specific antigens by Innolake. Innolake will utilize Escugen's EZWi-Fit® in its innovative ADC products, be responsible for the preclinical, clinical development, manufacturing, and commercial sales of these products worldwide, and make upfront payments, R&D and regulatory milestone payments to Escugen, as well as tiered royalties on global sales after commercialization.